HomeWomen's HealthResources for Women & PractitionersAntenatal Anti-D & Blood Products Information

Antenatal Anti-D & Blood Products Information

Guidelines for Blood Grouping & Antibody Screening in the Antenatal & Perinatal Setting

In 2007 the Australian and New Zealand Society of Blood Transfusion Ltd (ANZSBT) and Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) along with other members of the joint consultative committee (see guideline) collaborated to review the guideline:

Blood Grouping & Antibody Screening in the Antenatal & Perinatal Setting - March 2007

Rh(D) Antenatal Prophylaxis for Rh(D) Negative Women

Australian Red Cross

The Australian Red Cross Blood Service provides information and a downloadable FAQ fact sheet.

National Health and Medical Research Council (NHMRC) Guidelines

The National Blood Authority has produced a document Guidelines on the Prophylactic use of Rh (D) immunoglobulin (Anti-D) in obstetrics. Approved by the NHMRC, its aim is to inform clinicians, other health professionals and policymakers about the revised recommendations for the use of Anti-D in Australia.

National Blood Authority Guidelines(Australia)

Criteria for the Clinical use of Intravenous Immunoglobulin

For information outlining the products available and the conditions which do and don't meet the criteria for the clinical use of intravenous immunoglobulin, go to the National Blood Authority website:

Criteris for the Clinical Use of Intravenous Immunoglobulin (IVIg) in Australia

College Statement - Anti-D

Guidelines for the use of Rh (D) in obstetrics

C-Obs 6

Guidlines for the use of Rh (D) immunoglobulin (Anti-D) in obstetrics in Australia

These are guidelines that RANZCOG has developed for the use of Rh (D) immunoglobulin (Anti-D) in obstetrics in Australia. This College Statement was updated and subsequently endorsed by RANZCOG Council in March 2006.


 
Go to top

Copyright © 2011 Royal Australian and New Zealand College of Obstetricians and Gynaecologists. ABN: 34 100 268 969